ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1197

Periodontal Status Before Diagnosis in Patients with Rheumatoid Arthritis Predicts Cumulative Disease Activity in Years After Treatment Inititation
Abstract Number: 1198

Ultrasonography of the Median Nerve in Patients with Rheumatoid Arthritis Under Suspicion of Carpal Tunnel Syndrome
Abstract Number: 1199

Ultrasound in Clinically Suspect Arthralgia: The Role of Power Doppler to Predict Rheumatoid Arthritis Development
Abstract Number: 1200

Predicting Progression to RA in Patients with Seropositive Arthralgia
Abstract Number: 1201

Younger Age and Smoking Status Are Associated with Delayed Diagnosis of Rheumatoid Arthritis in a U.S. Veteran Population
Abstract Number: 1202

Widespread but Not Regional Non-articular Pain Influences Patient and Rheumatologist Reported Change in Clinical Disease Activity Index Scores over Time – Implications for Using Patient Ratings in Telehealth – a Study from the Canadian Early Arthritis Cohort
Abstract Number: 1203

A Change in a Patient Informed Clinical Disease Activity Index (PTCDAI) Is Similar to Their Rheumatologists CDAI When Following Patients with Early RA in the Canadian Early Arthritis Cohort (CATCH) Study
Abstract Number: 1204

CXCL13 Outranges DAS28CRP and CRP as Predictor of Long-term Radiographic Status in Early Rheumatoid Arthritis
Abstract Number: 1205

Predictors of Discordance Between Patient and Physician Global Assessment in Patients with Rheumatoid Arthritis
Abstract Number: 1206

Serum Levels of Total IgA Anti-cyclic Citrullinated Protein Antibodies Predict 11-year Radiographic Outcome in Early Rheumatoid Arthritis
Abstract Number: 1207

A Systematic Review Looking at the Relationship Between Serum Calprotectin and Ultrasound Parameters in Rheumatoid Arthritis
Abstract Number: 1208

Composite Articular Index Including Acute Phase Reactants Should Not Be Used in Patients with Rheumatoid Arthritis Treated with Il6 Inhibitors but May Be Useful in Those Receiving Jak Inhibitors: Ultrasound Evidence
Abstract Number: 1209

Plasma Calprotectin as a Biomarker of Active Synovitis in Rheumatoid Arthritis: A Clinical and Ultrasound Study in Patients Treated with Il6 and JAK Inhibitors
Abstract Number: 1210

Frequency of Anterior Atlanto-Axial Subluxation in Patients with Rheumatoid Arthritis
Abstract Number: 1211

Evaluation of the Cervical Involvement Frequency and Associated Risk Factors in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].